1887
  1. Home
  2. A-Z Publications
  3. Qatar Medical Journal
  4. Volume 2005, Issue 2
  5. Article
Volume 2005, Issue 2
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

Hepatitis C virus (HCV) is emerging as a public health issue in most counties worldwide. The prevalence of HCV infection varies among different geographical areas from 0.5% to 40% with an overall global prevalence of 3%. The WHO estimates that around 170 million people are chronically infected with HCV world wide. Hepatitis CV infection causes a slowly progressive liver disease in over 60% of infected individuals culminating into cirrhosis and ultimately leading to liver failure and hepatocellular carcinoma (HCC). Chronic liver disease due to HCV infection is now the leading indication for livertransplantation both in Europe and the USA. Although the incidence of acute hepatitis C has decreased over the last decade, the number of individuals with HCV-related liver disease continues to rise and is projected to peak around year 2015. As such HCV infection imposes a significant burden on the already exhausted health resources, particularly in the developing counties where the infection is endemic and its incidence is increasing.

© 2005 Bel Haj, Giaffer, licensee Bloomsbury Qatar Foundation Journals.
Loading

Article metrics loading...

/content/journals/10.5339/qmj.2005.2.7
2005-11-01
2024-11-08
Loading full text...

Full text loading...

References

  1. Wasley A, Alter MJ. Epidemiology of hepatitis C: Geographic differences and temporal trends. Semin Liver Dis. 2000; 20::1–6.
     [Google Scholar]
  2. Lauer G, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001; 345::41–52.
     [Google Scholar]
  3. Ponyard T, Yeun M-F, Ratziu V, Lai CL. Viral hepatitis C. Lancet. 2003; 362::2095–2100.
     [Google Scholar]
  4. Berengue M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. Hepatol. 2001; 35::666.
     [Google Scholar]
  5. Adam R, McMaster P, O'Grady JG, et al., Evaluation of liver transplantation in Europe: Report of the European Liver Transplant Registry. Liver Transpl. 2003; 9::1231–1243.
     [Google Scholar]
  6. Armstrong GL, Alter MJ, McQuilan GM, et al., The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology. 2003; 31::777–787.
     [Google Scholar]
  7. Villano SA, Vlahov D, Nelson KE, et al., Persistence ofviraemia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology. 1999; 29::908. 014.
     [Google Scholar]
  8. Thomas DL, Astemborski J, Rai RM, et al., The natural history of hepatitis C virus infection: host, viral and environmental factors. JAMA. 2000; 284::450–456.
     [Google Scholar]
  9. Gerlach JT, Diepolder HM, Zachoval R, et al., Acute hepatitis C: high rate of both spontaneous and treatment induced clearance. Gastroenterology. 2003; 125::80–88.
     [Google Scholar]
  10. Hofer H, Watkins-Riedel T, Janata O, et al., Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology. 2003; 37::60–64.
     [Google Scholar]
  11. Camma C, Almasio P, Craxi A. Interferon as treatment for acute hepatitis C: A metanalysis. Dig Dis Sci. 1996; 41::1248–1255.
     [Google Scholar]
  12. Quinn J. Inteferon therapy for acute hepatitis C viral infection. A review by metanalysis. Aust N J Med. 1997; 27::611–618.
     [Google Scholar]
  13. Thevenot T, Regimbeau C, Ratziu V, et al., Metanalysis of interferon randomized trials in treatment of viral hepatitis C in naive patients. 1999 update. J Viral Hepatitis. 2001; 8::48–62.
     [Google Scholar]
  14. Ponyard T, Regimbeau C, Myers RP, et al., Interferon for acute hepatitis C. Cochrane Database Systemic Review. 2002; I::CD000369.
     [Google Scholar]
  15. Alberti A, Boccato S, Vario A, Benvegnu L. Therapy of acute hepatitis C. Hepatology. 2002; 36::S195–S200.
     [Google Scholar]
  16. Vogel W, Graziadei I, Umlauft F, et al., High-dose interferon alpha-2b treatment prevents chronicity in acute hepatitis C: A pilot study. Dig Dis Sci. 1996; 41::81S–85S.
     [Google Scholar]
  17. Jackel E, Cornberg M, Wedemeyer H, et al., Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001; 345:20:1452–1457.
     [Google Scholar]
  18. Nomura H, Sou S, Tanimoto H, et al., Short-term interferon alfa therapy for acute hepatitis C: A randomized controlled trial. Hepatology. 2004; 39:4:1213–1219.
     [Google Scholar]
  19. Kamal SM, Ismail A, Graham S, et al., Pegylated interferon alpha therapy in acute hepatitis C: relations to hepatitis C virus specific T cell response kinetics. Hepatology. 2004; 39::1721–1731.
     [Google Scholar]
  20. Santantonia T, Fasano M, Sinisi E, et al., Efficacy of a 24-week course of PEG interferon _-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol. 2005; 3::329–333.
     [Google Scholar]
  21. Scotto G, Palombo E, fazio V, et al., Peginterferon alfa-2b treatment for patients affected by acute hepatitis C: presentation of six cases. Infection. 2005; 33::30–32.
     [Google Scholar]
  22. Wiegand J, Jackel E, Cornberg M, et al., Long-term follow-up after successful interferon therapy of acute hepatitis C. Hepatology. 2004; 40:1:89–107.
     [Google Scholar]
  23. Santantonio T, Sinisi E, Guastadisegni A, et al., Natural course of acute hepatitis C: a long-term prospective study. Dig Liver Dis. 2003; 35::104–113.
     [Google Scholar]
  24. Larghi A, Zuir M, Crosignani A, et al., Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmokinetics studies. Hepatology. 2002; 36::993–1000.
     [Google Scholar]
  25. Lehman M, Meyer MF, Monazahian M, et al., High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. J Med Virol. 2004; 73::387–391.
     [Google Scholar]
  26. McHutchinson JG, Gordon SC, Sciff ER, et al., Interferon alfa-2b alone or in combination with ribaverin as initial treatment for chronic hepatitis C. N Engl J Med. 1998; 339::1485–1492.
     [Google Scholar]
  27. Ponyard T, Marcellin P, Lee SS, et al., Randomised trial of interferon _-2b plus ribaverin for 48 weeks or for 24 weeks versus interferon _-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis CV. Lancet. 1998; 352::1426–1432.
     [Google Scholar]
  28. Sostegni R, Ghisetti V, Pittaluga F, et al., sequential vs concomitant administration of Ribaverin and interferon alpha n3 in patients with chronic hepatitis C not responding to interferon alone. Results of a randomized controlled trial. Hepatology. 1998; 28::341–346.
     [Google Scholar]
  29. Cheng SJ, Bonis PAL, Lau J, et al., Interferon and Ribaverin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a metanalysis of controlled and uncontrolled trials. Hepatolgy. 2001; 33::231–240.
     [Google Scholar]
  30. Fargion S, Bruno S, Borzio M, et al., Sustained response to combination therapy in patients with chronic hepatitis C who failed to respond to interferon. J Hepatol. 2003; 38::499–505.
     [Google Scholar]
  31. Ponyard T, Marcellin P, Bissey A, et al., Reinforced interferon alpha-2b and Ribaverin is more effective than standard combination therapy in the treatment of chronic hepatitis C previously non-responsive to interferon: a randomized trial. J Viral Hepatitis. 2003; 10::197–204.
     [Google Scholar]
  32. Fattovich G, Zagni I, Ribero ML, et al., A randomized trial of prolonged high dose of interferon plus ribaverin for hepatitis C patients nonresponders to interferon alone. J Viral Hepatitis. 2004; 11::543–551.
     [Google Scholar]
  33. Manns MP, McHutchinson JG, Gordon SC, et al., Peginterferon alfa-2b plus ribaverin compared with interferon alfa-2b plus ribaverin for initial treatment of chronic hepatitis C. A randomized trial. Lancet. 2001; 358::958–965.
     [Google Scholar]
  34. Fried MW, Shiffman ML, Reddy KR, et al., Peginterferon alfa-2a plus ribaverin for patients with chronic hepatitis C infection. N Eng J Med. 2002; 347::975–982.
     [Google Scholar]
  35. Sulkowski M, Rothstein KD, Stein L, et al., Peginterferon alfa-2b plus ribaverin for treatment of patients with chronic hepatitis C who have previously failed to achieve a sustained response following interferon alfa or interferon alfa-2b plus ribaverin. Hepatology. 2001; 34:4 pt 2:419.
     [Google Scholar]
  36. Jacobson IM, Russo MW, Brown RS, et al., Pegylated interferon alfa-2b plus ribaverin in patients with chronic hepatitis C: A trial in prior nonresponders to interferon monotherapy or combination therapy and in combination therapy relapsers. Gastroenterology. 2001; 120:suppl:383 A.
     [Google Scholar]
  37. Dalke DD, Donovan J, Goff J, Monsour H. PEGI2000 interferon alfa-2b 0.5 mcg/kg + ribaverine 800 mg/day vs PEGI 2000 interferon alfa-2b 1.5 mcg/kg + ribaverin 800 mg/day for 48 weeks for treatment of patients with hepatitis C who failed to or relapsed after treatment with combination therapy (Rebetram)-interim results. Hepatology. 2001; 34:4 pt 2:353A.
     [Google Scholar]
  38. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al., Peginterferon alfa-2a and ribaverin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology. 2004; 126::1015–1023.
     [Google Scholar]
  39. Sherman M, Bain V, Villeneuve JP, et al., The management of chronic viral hepatitis: a Canadian Consensus Conference (review). Canadian J Gastroenterol. 2004; 18:12:715–718.
     [Google Scholar]
  40. Orient H, Vrolijk JM, Veldt BJ, Schalm SW. Hepatitis C 2002 guidelines: summary annotations. Supplement Scand J Gastroenterol. 2003; 239:105–110.
     [Google Scholar]
  41. Anonymous. Recommendations for the National Institute of Health Consensus Development Conference Statement: Management of hepatitis C: 2002. Hepatology. 2002; 36:5:1039.
     [Google Scholar]
  42. Booth JCL, O'Grady J, Neuberger J. Clinical guidelines on the management of hepatitis C. Gut. 2001; 49:suppl 1:11–21.
     [Google Scholar]
  43. Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase level. Hepatology. 1997; 26:suppl 1:133S.
     [Google Scholar]
  44. Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase level. Hepatology. 2002; 36:5 suppl 1:SI79–S184.
     [Google Scholar]
  45. Shakil AD, Conry-Cantilena C, Alter HJ, et al., Volunteer blood donors with antibodies to hepatitis C virus: Clinical, biochemical, virologic and histologic factors. The Hepatitis Study Group. Ann Intern Med. 1995; 123::330–337.
     [Google Scholar]
  46. Piton A, Ponyard T, Iambert-Bismut F, et al., Factors associated with serum alanine transferase activity in healthy subjects. Consequences for the definition of normal values for the selection of blood donors and for patients with chronic hepatitis C. Hepatology. 1998; 27::1213–1219.
     [Google Scholar]
  47. Inglesby TV, Rai R, Astemborski J, et al., A prospective, community based evaluation of liver enzymes in individuals with hepatitis C after drug use. Hepatology. 1999; 29::590–596.
     [Google Scholar]
  48. Pradat P, Alberti A, Ponyard T, et al., Predictive value of ALT levels for histological findings in chronic hepatitis C. A European Collaborative Study. Hepatology. 2002; 36::973–977.
     [Google Scholar]
  49. Prati D, Taioli E, Zanella A, et al., Updated definitions of healthy ranges for serum alanine transferase levels. Ann Intern Med. 2002; 137::1–10.
     [Google Scholar]
  50. Alberti A, Noventa F, Benvegnu L, et al., Prevalence of disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med. 2002; 137::961–964.
     [Google Scholar]
  51. Shiffman ML, Stewart CA, Hoffmann CM. Chronic infection with hepatitis C virus in patients with elevated and persistently normal serum alanine aminotranferase levels: Comparison of hepatic histology and response to interferon therapy. J Infect Dis. 2000; 182::1595–1601.
     [Google Scholar]
  52. Stanley AJ, Hay den GH, Pris J, et al., Assessment of liver histology in patients with normal transaminase levels. Eur J Gastrohepatol. 1996; 8::869–872.
     [Google Scholar]
  53. Serfaty L, Chazouillers O, et al., Pawlotski.Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity. Gastroenterology. 1996; 110::291–295.
     [Google Scholar]
  54. Lee SS, Sherman M. Pilot study of interferon and ribaverin treatment in patients with chronic hepatitis C and normal aminotransferase levels. J Viral Hepatitis. 2001; 8::202–205.
     [Google Scholar]
  55. Jacobson IM, Ahmed F, Russo MR, et al., Interferon alpha-2b and ribaverin for patients with chronic hepatitis C and normal ALT. Am J Gastroenterol. 2004; 99::1700–1705.
     [Google Scholar]
  56. Manegement of hepatitis C: 2002. NIH Consensus Statement 2002 Jun 10-12; 19(3): 1-46.
  57. Zeuzem S, Diago M, Gane E, et al., Peginterferon alfa-2a (40 kilodaltons) and ribaverine in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology. 2004; 127::1724–1732.
     [Google Scholar]
  58. Ishak K, Baptista A, Bianchi L, et al., Histological grading and staging of chronic hepatitis. J Hepatol. 1995; 22::696–699.
     [Google Scholar]
  59. Knodell R, Ishak K, Black W, et al., Formulation and application of numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981; 1::431–435.
     [Google Scholar]
  60. Bedossa P, Ponyard T. For the METAV1R Cooperative Study Group. An algorithm for the grading activity in chronic hepatitis C. Hepatology. 1996; 24::289–293.
     [Google Scholar]
  61. Hui CK, Belaye T, Montegrande K, Wright TL. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. J Hepatol. 2003; 38::511–517.
     [Google Scholar]
  62. Ghany MG, Kleiner DE, Alter H, et al., Progression of fibrosis in chronic hepatitis C. Gastroenterology. 2003; 124::97–104.
     [Google Scholar]
  63. Hopf V, Meller B, Kuther D, et al., Long-term follow-up of post transfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV). J Hepatol. 1990; 10::69–75.
     [Google Scholar]
  64. Mattson L, Sonnenberg A, We Hand O. Outcome of acute symptomatic non-A, non-B hepatitis: A 13-year follow-up study of hepatitis C virus markers. Liver. 1993; 13::274–278.
     [Google Scholar]
  65. Kobayashi M, Tanaka E, Sodeyama T, et al., The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses. Hepatology. 1996; 23::695–699.
     [Google Scholar]
  66. Marcellini P, Asselah T, Bayer N. Fibrosis and disease progression in hepatitis C. Hepatology. 2002; 36:5 suppl 1:547–556.
     [Google Scholar]
  67. Alberti A, Noventa F, Benvegnu L, et al., Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med. 2002; 137::961–964.
     [Google Scholar]
  68. Ponyard T, Ratziu V, Benmanov Y, et al., Fibrosis in patients with chronic hepatitis C: detection and significance. Semin Liver Dis. 2000; 20::47–55.
     [Google Scholar]
  69. Hirsch KR, Wright TL. The dilemma of disease progression in hepatitis C patients with normal serum aminotransferase levels. Am J Gastroenterol. 2000; 109::66–67.
     [Google Scholar]
  70. Solomon JR, Weinstein MC, Hammitt JK, et al., Cost effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA. 2003; 290::228–237.
     [Google Scholar]
  71. Queneau PE, Osaer F, Bronowicki JP, et al., Treatment of mild chronic hepatitis C with interferon alfa-2b: Results of a multicentre randomized study in 80 patients. Eur J Gastroenterol Hepatol. 2001; 13::143–147.
     [Google Scholar]
  72. Verbaan HP, Wide A, Bondeson TL, et al., high sustained response rate in patients with histologically mild (low grade and stage) chronic hepatitis C infection. A randomized, doubleblind placebo controlled trial of interferon alpha-2b with and without ribaverin. Eur J Gastroenterol Hepatol. 2002; 14::627–633.
     [Google Scholar]
  73. Wright M, Fortan D, Main J, et al., Treatment of histologically mild hepatitis C virus infection with interferon and ribaverin: A multicentre randomized controlled trial. J Viral Hepatitis. 2005; 12::58–66.
     [Google Scholar]
/content/journals/10.5339/qmj.2005.2.7
Loading
  • Article Type: Editorial

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error